Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK

por Vega-Hernandez, Gabriela, Wojcik, Radek, Schlueter, Max
Publicado 2017

Caregiver burden in cystic fibrosis: a systematic literature review

por Daly, Conor, Ruane, Philip, O’Reilly, Karl, Longworth, Louise, Vega-Hernandez, Gabriela
Publicado 2022

Patients' with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes

por Feher, Michael D, Brazier, John, Schaper, Nicolaas, Vega-Hernandez, Gabriela, Nikolajsen, Annie, Bøgelund, Mette
Publicado 2016

Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain

por Mezquita-Raya, Pedro, Ramírez de Arellano, Antonio, Kragh, Nana, Vega-Hernandez, Gabriela, Pöhlmann, Johannes, Valentine, William J., Hunt, Barnaby
Publicado 2017

Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom

por Feher, Michael, Vega-Hernandez, Gabriela, Mocevic, Emina, Buysse, Brian, Myland, Melissa, Power, Geraldine S., Nystrup Husemoen, Lise L., Kim, Joseph, Witte, Daniel R.
Publicado 2017

PCR-assisted impedimetric biosensor for colibactin-encoding pks genomic island detection in E. coli samples

por Solis-Marcano, Nadja E., Morales-Cruz, Myreisa, Vega-Hernández, Gabriela, Gómez-Moreno, Ramón, Binder, Claudia, Baerga-Ortiz, Abel, Priest, Craig, Cabrera, Carlos R.
Publicado 2021